Starting in 2030, Söderenergi will have the capacity to annually capture and permanently store up to 500,000 tonnes of biogenic carbon dioxide from the Igelsta plant in Södertälje. Söderenergi is currently working on project planning, and in order to make an investment decision by the end of 2026, the entire value chain must be in place – from carbon capture to geological storage and certified carbon credits.
"We are happy and proud that the first negative emissions from our facility end up at AstraZeneca, a company with roots in Södertälje. The agreement shows confidence in our bio-CCS project and contributes to building up the industry for negative emissions," said Robert Tingvall, CEO of Söderenergi.
Permanent negative emissions are an important tool to compensate for the emissions that cannot be avoided and in order to achieve the goals of the Paris Agreement by 2050, negative emissions are necessary.
"The agreement with Söderenergi is an important complement to the climate goals of halving our greenhouse gas emissions by 2030 and reducing them by 90 percent by 2045 throughout the value chain," said Marika Du Rietz, Head of Sustainability at AstraZeneca in Södertälje."
For Södertälje and southern Greater Stockholm, the investment is important for several reasons.
"Carbon dioxide removal is a fantastic investment by Söderenergi, and it is particularly gratifying that AstraZeneca is involved," said Boel Godner, Chairman of the Municipal Executive Board in Södertälje. In the long term, it is about building an energy and climate cluster and taking responsibility for achieving the region's and Sweden's climate goals."